U.S. Olympic gold medal-winning athlete Lindsey Vonn is once again teaming up with infectious disease biopharma Invivyd for a ...

For the second time in a span of four months, Insmed’s Brinsupri has come up short in a mid-stage trial designed to expand ...

One year into his tumultuous tenure as the FDA’s commissioner, Marty Makary, M.D., has laid out ambitious internal goals and ...

The plummeting demand for Merck & Co.’s HPV vaccine Gardasil in China has forced the New Jersey drugmaker to rework its ...

As drugmakers strive to fine tune the delivery of their medications for better convenience and patient adherence, Halozyme is putting a recent acquisition in the space to work, thanks to a new tie- | ...

As biotechs face increasingly tight development timelines, scale-up headaches and, more recently, unpredictable policy fluctuations, one way to stand out as a CDMO partner is picking a specialty an | ...

The FDA is seeking (PDF) new powers to hold companies accountable for misleading direct-to-consumer (DTC) ads, adding legislat | The FDA is seeking new powers to hold companies accountable for ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. | ...

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

The doctors at fictional Sacred Heart Hospital are in, and so is Insulet’s real-life wearable insulin management system ...

Forget March going out like a lamb. On the M&A landscape, March went out like a lion.  | In a flurry of activity, biopharma ...